Filing Flows › Kyntra Bio (KYNB) › Q1 2025
Kyntra Bio (KYNB) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Kyntra Bio (KYNB) reported revenue of $2.7M for the first quarter 2025 (Q1 2025), -89% from a year earlier. Operating margin was -544.7%, net earnings $4.6M (169.4% of revenue).
Kyntra Bio, Q1 2025: revenue $2.7M (-89% year over year), operating margin -544.7%, net earnings $4.6M, operating cash flow $2.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.7M | — | -89% |
| Operating profit | −$14.9M | — | — |
| Net earnings | $4.6M | — | — |
| Operating cash flow | $2.7M | — | — |
| Free cash flow | $2.7M | — | — |
What changed
Revenue was $2.7M in Q1 2025, down 89% year over year. Drug Product Revenue was the largest line at 95% of revenue. Drug Product Revenue lost $21.9M year over year (down 89%), 97% of the total change.
Operating costs exceeded revenue by $14.9M, an operating margin of -544.7%. Total costs fell 76% while revenue fell 89%. Net earnings were $4.6M. The effective tax rate was 0.0%. Non-operating items added $19.6M, 421% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $2.7M, 59% of net earnings. Non-cash charges added back $318K of depreciation and $2.9M of share-based compensation. Working capital and other items used $5.1M. Capital expenditures of $16K left free cash flow of $2.7M.
Questions
What was Kyntra Bio's revenue in the first quarter 2025?
Kyntra Bio (KYNB) reported revenue of $2.7M for the first quarter 2025 (Q1 2025), -89% from a year earlier.
Was Kyntra Bio profitable in the first quarter 2025?
Operating loss was $14.9M (-544.7% of revenue) and net earnings $4.6M.
Source: Kyntra Bio 10-Q on SEC EDGAR.